Lipella Pharmaceuticals Patents – Key Insights and Stats

Lipella Pharmaceuticals has a total of 34 patents globally, out of which 5 have been granted. Of these 34 patents, More than 20% patents are active. The United States of America is where Lipella Pharmaceuticals has filed the maximum number of patents, followed by Europe and Japan. Parallelly United States of America seems to be the main focused R&D center and also is the origin country of Lipella Pharmaceuticals.

Lipella Pharmaceuticals was founded in 2005 by Michael Chancellor and Jonathan Kaufman. Lipella Pharmaceuticals operates as a clinical-stage biotechnology company. The Company focuses on developing proprietary drug delivery platform that optimizes drug delivery to mucosal membranes for the treatment of cancer survivors. Lipella Pharmaceuticals Pharmaceuticals serves customers in the United States.

 Do read about some of the most popular patents of Lipella Pharmaceuticals which have been covered by us in this article and also you can find Lipella Pharmaceuticals patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Lipella Pharmaceuticals patent portfolio.

How many patents does the Founder and CEO of Lipella Pharmaceuticals have?

The Founders and CEO Jonathan Kaufman has 29 patents and Co-Founder Michael Chancellor has 163 Patents.                           

How many patents does Lipella Pharmaceuticals have?

Lipella Pharmaceuticals has a total of 34 patents globally. These patents belong to 6 unique patent families. Out of 34 patents, 7 patents are active.

How Many Patents did Lipella Pharmaceuticals File Every Year?

Lipella Pharmaceuticals Patents Filing Trend

Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.

Year of Patents Filing or GrantLipella Pharmaceuticals Applications FiledLipella Pharmaceuticals Patents Granted
200913
20102
20111
201231
20132
201481
20153
20181
202012
20221

How many Lipella Pharmaceuticals patents are Alive/Dead?

Worldwide Patents

Lipella Pharmaceuticals Patents Portfolio

How Many Patents did Lipella Pharmaceuticals File in Different Countries?

Lipella Pharmaceuticals Worldwide Patents

Countries in which Lipella Pharmaceuticals Filed Patents

CountryPatents
United States of America14
Europe3
Japan3
Canada2
Australia2
Brazil1
China1
Korea1
Mexico1

Where are Research Centers of Lipella Pharmaceuticals Patents Located?

The research centers of all the Lipella Pharmaceuticals patents is the United States of America.

10 Best Lipella Pharmaceuticals Patents

US20100166739A1 is the most popular patent in the Lipella Pharmaceuticals portfolio. It has received 28 citations so far from companies like Boston Scientific, Medtronic and Mologic Limited.

Below is the list of 10 most cited patents of Lipella Pharmaceuticals:

Publication NumberCitation Count
US20100166739A128
US20130071466A126
EP2273976A221
US20120263781A112
WO2009139984A29
US20100104631A15
US20150030667A14
US20150037402A13
WO2015154007A13
US20160045623A12

What Percentage of Lipella Pharmaceuticals US Patent Applications were Granted?

Lipella Pharmaceuticals (Excluding its subsidiaries) has filed 14 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 1 have been granted leading to a grant rate of 8.33%.

Below are the key stats of Lipella Pharmaceuticals patent prosecution at the USPTO.

Which Law Firms Filed Most US Patents for Lipella Pharmaceuticals

Law FirmTotal ApplicationsSuccess Rate
Pabst Patent Group Llp1011.11%
Troutman Pepper Hamilton Sanders Llp40.00%

List of Lipella Pharmaceuticals Patents –

Publication NumberTitle
US11357725B2Delivery Of Agents Using Metastable Liposomes
US10639278B2Delivery Of Agents Using Metastable Liposomes
US20190094323A1Systems And Methods Of Detecting Interstitial Cystitis
US20170189564A9Systems And Methods Of Detecting Interstitial Cystitis
US20160045623A1Systems And Methods To Image Intercellular And Intercompartmental Defects With Magnetic Resonance Imaging (Mri)
US20150037402A1Methods And Compositions For Treating Gastric Disorders
US20150030667A1Compositions And Methods For Treating Underactive Bladder
US20130071466A1Methods And Compositions For Treating Gastric Disorders
US20120301540A1Method Of Treatment For Bladder Dysfunction
US20120263781A1Methods And Compositions For Treating Rhinitis
US20120093920A1Method Of Treatment For Bladder Dysfunction
US20110274745A1Instillation Of Liposomal Formulation Of Sirna And Antisense Oligonucleotides
US20100166739A1Methods And Compositions For Diagnosing Urological Disorders
US20100104631A1Method Of Treatment For Bladder Dysfunction
EP3060197A1Delivery Of Agents Using Metastable Liposomes
EP2599476A1Treatment Of Bladder Dysfunction Using Liposomal Botulinum Toxin
EP2273976A2Treatment Of Bladder Dysfunction Using Liposomal Botulinum Toxin
CN102065841ATreatment Of Bladder Dysfunction Using Liposomal Botulinum Toxin
WO2015061449A9Delivery Of Agents Using Metastable Liposomes
WO2015154007A1Systems And Methods Of Detecting Interstitial Cystitis
WO2013116822A1Methods And Compositions For Treating Gastric Disorders
WO2011060065A3Instillation Of Liposomal Formulation Of Sirna And Antisense Oligonucleotides
WO2010078403A3Methods And Compositions For Diagnosing Urological Disorders
WO2009139984A2Method Of Treatment For Bladder Dysfunction
JP2016534087ADrug Delivery Using Metastable Liposomes
JP5538359B2Treatment Of Bladder Dysfunction Using Liposomal Botulinum Toxin
JP2014062125ATreatment For Bladder Dysfunction Using Liposomal Botulinum Toxin
AU2014340137B2Delivery Of Agents Using Metastable Liposomes
CA2927356A1Delivery Of Agents Using Metastable Liposomes
AU2009246834B2Treatment Of Bladder Dysfunction Using Liposomal Botulinum Toxin
CA2720523A1Treatment Of Bladder Dysfunction Using Liposomal Botulinum Toxin
BRPI0911098A2Liposomal Formulation And Method For Treatment Of Hyperactive Bladder.
MX2010010635ATreatment Of Bladder Dysfunction Using Liposomal Botulinum Toxin.
KR1020100131471ATreatment Of Bladder Dysfunction Using Liposomal Botulinum Toxin

EXCLUSIVE INSIGHTS COMING SOON!

What are Lipella Pharmaceuticals key innovation segments?

What Technologies are Covered by Lipella Pharmaceuticals?

The chart below distributes patents filed by Lipella Pharmaceuticals in different countries on the basis of the technology protected in patents. It also represents the markets where Lipella Pharmaceuticals thinks it’s important to protect particular technology inventions.

R&D Focus: How has Lipella Pharmaceuticals search focus changed over the years?

EXCLUSIVE INSIGHTS COMING SOON!

Interested in knowing about the areas of innovation that are being protected by Lipella Pharmaceuticals?

Updated on August 5, 2022

Was this article helpful?

Leave a Comment